Home » AstraZeneca
Tag:

AstraZeneca

Health

If you are one of those who have not been infected with the Corona virus… find out why

by archyde

Scientists say that some people may never contract the Corona virus thanks to their genes, as researchers from Oxford University found that people with a certain mutation produce a greater response to antibodies after vaccination.

About 30 to 40 percent of people have the gene known as HLA-DQB1*06, and the enhanced protection may be enough to prevent infection completely, and may explain in part why some people don’t contract the virus, even when family members have it.
The United States has the largest number of confirmed cases of any country in the world at 179 million, which is equivalent to more than half of the total population, but this is likely to be inaccurate, because testing was incomplete at the beginning of the outbreak and some people did not They are never tested.
However, there are many anecdotal stories of people who infected their entire family with the virus and avoided infection even after sharing a bed with a sick person.
This group of people has been dubbed “Never Covid” and scientists have never figured out how to manage it.
Lead researcher Dr Alexander Mintzer said: “We’ve seen wide variation in how quickly people test for COVID after vaccination, and our findings suggest that our genetic code may influence how likely this is to happen over time.”
Scientists examined blood samples from people in five different experiments, which looked at 1,600 adults who received the “Pfizer-BioNTech” vaccine or the “AstraZeneca” vaccine as an initial dose, and it was found that individuals who have this gene have a high percentage of proteins that protect the body. There is more virus in their blood than those without this gene.
They also looked at a group of people who took Covid tests every week for more than a year after receiving their first dose, and those with the HLA-DQB1*06 gene were unlikely to have contracted the virus over a 12-month period.
Co-author Professor Julian Knight added: “From this study we have evidence that our genetic makeup is one reason why we differ from one another in our immune response after Covid vaccination.”

0 comment
0 FacebookTwitterEmail
Health

» Alexion: Ultomiris obtains Marketing Authorization in the treatment of acquired generalized myasthenia gravis MyPharma Editions

by archyde
Posted on Tuesday, October 4, 2022

Alexion, AstraZeneca Rare Disease, Announces European Commission Marketing Authorization for Ultomiris (ravulizumab)* as a New Therapeutic Option for the Treatment of Adult Patients with Acquired Generalized Myasthenia Gravis (GAM) at anti-acetylcholine receptor (AChR) antibodies.

This marketing authorization represents a significant step in the management of MAg as the first treatment available in France, the frequency of administration of the maintenance dose of which is every two months and which aims to inhibit of the C5 protein in the terminal part of the complement cascade, an element of the immune system 1. This rare and serious autoimmune neuromuscular disease is characterized by severe muscle weakness caused by the presence of autoantibodies directed against the membrane neuromuscular junction postsynaptic 1. The prevalence of myasthenia gravis is estimated at approximately 89,000 people in Europe 1-9.

The award granted by the European Commission succeeds the opinion of the Committee for Medicinal Products for Human Use and is based on the results of the phase III CHAMPION-MG trial published in NEJM Evidence. In the study, Ultomiris demonstrated superiority at week 26 over placebo on the primary endpoint, which assessed score within the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL), a medical assessment of people living with the disease 9-10. The clinical benefit of Ultomiris was observed up to 60 weeks 11-12.

“By directly targeting the complement system involved in the disease, this treatment will constitute a new option for people with myasthenia gravis, we are delighted about it” declared Pierre Boulanger, President of the Association des Myasthéniques Isoles et Solidaires (AMIS) .

“Generalized acquired myasthenia gravis is a rare disease that can have a major impact not only medical, but also social because of the variability of symptoms in space and time,” said Professor Attarian, Head of the Neuromuscular and Neuromuscular Diseases Department. Amyotrophic Lateral Sclerosis at La Timone Hospital and coordinator of the FILNEMUS Neuromuscular sector. “This new therapeutic alternative will join the arsenal of treatments that allows neurologists to manage the disease at an early stage”.

“This new European marketing authorization is part of our long-standing commitment to people suffering from rare diseases. This indication in neurology represents a new advance in our R&D in understanding the role and impact of the complement system,” said Céline Khalifé, General Manager of Alexion, France, Belgium, and Luxembourg. “We are committed to the rapid availability of this new indication, so the innovative character was recognized by an early access granted a few months ago”.

Ultomiris was approved in the United States in April 2022 and in Japan in August 2022 for adults with MAg to AChR. Regulatory assessments are underway in other countries. In the CHAMPION-MG clinical study, the safety profile of Ultomiris is comparable to placebo and consistent with data observed in phase 3 clinical studies of the molecule in paroxysmal nocturnal hemoglobinuria (PNH) and hemolytic uremic syndrome atypical (aHUS). The most common adverse effects are: diarrhoea, upper respiratory tract infections, nasopharyngitis and headaches 9.

___________________________

References :
1. HAS, https://www.has-sante.fr/upload/docs/application/pdf/2015-07/pnds_-_myasthenie_autoimmune.pdf, (site consulted in September 2022)
2. Westerberg E, Punga AR. Epidemiology of Myasthenia Gravis in Sweden 2006–2016. Brain Behav. 2020;10:e01819. https://doi.org/10.1002/brb3.1819
3. Anil, R., Kumar, A., Alaparthi, S., Sharma, A., Nye, JL., Roy, B., O’Connor, KC., Nowak, R., (2020). Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry – The EXPLORE-MG registry. J Neurol Sci. 2020 Jul 15;414:116830.
4. Oh SJ., (2009). Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. Journal of Clinical Neurology. 2009b Jun 1;5(2):53-64.
5. Fang, F., Sveinsson O., Thormar G., Granqvist M., Askling J., Lundberg IE., Ye W., (2015). The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med 2015; 277:594–604.
6. Lefter, S., Hardiman, O., Ryan, A., (2017). A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 2017;88:304–313.
7. Pallaver, F., Riviera, AP., Piffer, S., Ricciardi, R., Roni, R., Orrico, D., Bonifati, DM., (2011). Change in Myasthenia Gravis Epidemiology in Trento, Italy, after Twenty Years. Neuroepidemiology 2011;36:282–287.
8. Santos, E., Coutinho, E., Moreira, I., et.al., (2016). Epidemiology of Myasthenia Gravis in Northern Portugal: Frequency Estimates and Clinical Epidemiological Distribution of Cases. Muscle Nerve 2016; 54: 413–421. 9. Dresser, Laura et al. (2021) “Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.” Journal of clinical medicine vol. 10,11 2235. 21 May. 2021, doi:10.3390/jcm10112235
10. Vu, Tuan, et al. (2022) « Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. » NEJM Evidence 1.5 (2022): EVIDoa2100066.
11. Tanaka, Kazuki et al. (2021) “The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.” Pediatric nephrology (Berlin, Germany) vol. 36,4 (2021): 889-898. doi:10.1007/s00467-020-04774-2
12. Vu, T et al. (2022). Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid 2022; 1 (5)
13. ClinicalTrials.gov. Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis. NCT Identifier: NCT03920293. Available here. Accessed March 2022.
14. Conti-Fine, Bianca M et al. (2006) “Myasthenia gravis: past, present, and future.” The Journal of clinical investigation vol. 116,11 (2006): 2843-54. doi:10.1172/JCI29894
15. Grob, David et al. (2008) “Lifetime course of myasthenia gravis.” Muscle & nerve vol. 37,2 (2008): 141-9. doi:10.1002/mus.20950
16. Lee, Ikjae et al. (2018) “Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry.” Muscle & nerve, 10.1002/mus.26104. 21 Feb. 2018, doi:10.1002/mus.26104
17. Engel-Nitz, Nicole M et al. (2018) “Burden of illness in patients with treatment refractory myasthenia gravis.” Muscle & nerve, 10.1002/mus.26114. 27 Feb. 2018, doi:10.1002/mus.26114
18. Boscoe, Audra N et al. (2019) “Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life.” Journal of clinical neuromuscular disease vol. 20,4 (2019): 173-181. doi:10.1097/CND.0000000000000257
19. Howard, J. F., (2017). Myasthenia gravis: the role of complement at the neuromuscular junction. Annals of The New York Academy of Sciences, 1412(1), 113-128. https://doi.org/10.1111/nyas.13522

Source and visual: Astrazeneca

Share the post “Alexion: Ultomiris obtains Marketing Authorization in the treatment of acquired generalized myasthenia gravis”

0 comment
0 FacebookTwitterEmail
Health

Doctor Yong reveals information about “3 needle vaccination” against omicron, which type is effective and which is not.

by archyde

(December 10, 2021) Issue “New species of covids” Omikron (Omicron) Prof. Dr. Yong Phuworawan (Mor Yong) Head of the center specializing in clinical virology Faculty of Medicine Chulalongkorn University Facebook post reveals information about “Three needle vaccinations” provoke behindinactivated vaccine Which type works well which type does not work

If the resistance to Spike proteins was measured, mRNA activation had the highest immunity, followed by virus vectors, followed by dead bacteria.

inactivated vaccineThe whole viral portion contained a nucleocapsid, thus detecting immunity to the nucleocapsid. Serum IgA assays, high response in mRNA andVirus more than inactivated vaccines as previously mentioned Inactivated vaccines are a good start. But it is a bad activator to activate. A virus vector or mRNA vaccine should be used.

Facebook source: M.Yong

0 comment
0 FacebookTwitterEmail
Health

It has arrived. “Anti-Covid Injection” O Micron, test results found that it is effective against BA.4-BA.5

by archyde

Stick to the situation of the Covid-19 outbreak Omicron BA.4 and BA.5 is starting to spread more and from the information found such species There is a strong tendency to spread and spread relatively well in the lower respiratory tract, as well as the Delta species. Of course, the booster vaccination can still prevent infectionCOVIDat a certain level But nowadays, innovation, technology, and medicine prevent covid 19 have more Many vaccine companies and “Anti-Covid Injection” out to reduce the rate of infection And died for the world’s population and of course believe that many people have heard the term. LAAB or some combination of long-acting antibodies But there may still be questions such as who is suitable for use and how including being able to prevent the spread of COVID-19 Is it true? And how long does it work, etc. Today we have compiled the answers to all your questions here. and ready to take you to get to know LAAB or “Anti-Covid Injection” give more

1.LAAB Abbreviated for Long-acting Antibody, or long-acting combination antibody. Used for prevention before exposure to the virus that causes COVID-19. which can neutralize the activity of Omicron subspecies virus BA.1 BA.1.1 BA.2 BA.3 BA.4 and BA.5 Yes, as well as being able to reduce the risk of contracting COVID-19. with symptoms as well

2.LAAB It can be used in people 12 years of age and older (over 40 kg body weight) who are immunocompromised and who may have an immune response to the COVID-19 vaccine. insufficient from co-morbidities such as cancer patients organ transplant patients Patients receiving immunosuppressants, dialysis patients including those who cannot receive the vaccine against COVID-19

3. For use LAAB It is an intramuscular injection of 150 mg each of the hips, with research supporting that a single injection can provide at least some protection against infection with the COVID-19 virus.
6 months

Follow more social media trends https://www.facebook.com/komchadluek/

4. Present LAAB “Anti-Covid Injection” Has been registered in many countries around the world, such as the United States. united kingdom Including the European Union and more than 30 countries around the world for prevention before exposure to the virus that causes COVID-19.

5. If there is a question that the general public can take medicine LAAB Yes, I must say that LAAB is initially registered for use in vulnerable populations. high risk and have immune deficiency problems including those who cannot be vaccinated first

6. Recently AstraZeneca has announced results from TACKLE, a phase 3 study to treat COVID-19 patients. with mild to moderate symptoms which shows the efficiency of LAAB in use to prevent severe disease and prevent death The results of this study indicate that LAAB can play a role in the treatment of COVID-19 which has to wait for registration for future use

7. LAAB has well-tolerated side effects. And no security issues have been identified. The most common side effects were injection site reactions. Most of them have mild to moderate symptoms and can go away on their own.

Follow more news https://www.komchadluek.net/

0 comment
0 FacebookTwitterEmail
Economy

AstraZeneca releases positive new data on its anti-Covid drug

by archyde

British pharmaceutical giant AstraZeneca on Wednesday released new positive data from a phase 3 trial for its anti-Covid-19 drug Evusheld.

These results published in the journal The Lancet Respiratory Medicine show that “Evusheld” provides significant statistical protection against progression to a severe form of Covid-19 or death compared to the use of a placebo”, writes AstraZeneca in a press release. This trial “shows the benefit of outpatient treatment with Evusheld of mild to moderate cases of Covid-19”, according to the group. In this trial called TACKLE, “90% of the participants had a risk of progression of their Covid-19 to a severe form due to comorbidities or their age”, notes the laboratory.

The trial was conducted at 95 sites in the United States, Latin America, Europe and Japan with 903 participants. “Despite the success of vaccines, many people, especially the elderly or those with co-morbidities or who are immunocompromised, are still at risk of severe forms of Covid-19,” commented Hugh Montgomery, professor of intensive care at University College London and the one of the test managers. “Other options are needed to prevent disease progression and reduce the pressure on health systems, particularly in view of the emergence of new variants,” he added, quoted in the press release. “We continue to discuss the TACKLE results with regulators,” said Mene Pangalos, executive vice president of biopharmaceutical research at AstraZeneca.

Evusheld has marketing authorization in the European Union and conditional authorization in Great Britain for preventive treatments. A monoclonal antibody, this drug is also authorized in certain specific cases in the United States and applications for authorization in the prevention or treatment of Covid-19 are under study in several other countries.

British pharmaceutical giant AstraZeneca on Wednesday released new positive data from a phase 3 trial for its anti-Covid-19 drug Evusheld.
These results published in the journal The Lancet Respiratory Medicine show that Evusheld “provides significant statistical protection against progression to a severe form of Covid-19 or death compared to…

0 comment
0 FacebookTwitterEmail
Health

Monkey smallpox is not released from the lab. No country has locked down yet.

by archyde

The genetic sequence we have so far for all viruses traces back to the disease strain.monkey poxthat are often spread in West Africa “That tells us that This virus is not something that is produced in a lab,” Tokhmafchan said.

The UK in 2018 and 2021 hadmonkey poxJust a handful And there will also be a large outbreak of monkeypox in the United States in 2021, in which each person has been infected by a person traveling to the country or from an imported animal.

Prof Horby said: “So it’s very possible that’s what happened this time. And it’s the most likely scenario.”

And the earliest cases identified in the UK during the current outbreak came from a traveler from Nigeria.

For the idea that monkeypox came out of the lab. “There is no basis for that claim at all,” Prof Horby said.

There is no evidence that an outbreak was planned.

There are claims online that the outbreak ofmonkey poxAt present this is intentional planning. Many pointed to billionaires like Bill Gates or Dr Anthony Fauci to reflect on the conspiracy theory of COVID-19.

This baseless confirmation is being shared in the Russian media. Chinese social apps such as Weibo and Instagram can also be found on Facebook in Romanian, German, English, Arabic, French, Slovenian, Hungarian and Punjabi.

The claim points to a document released by the US biosecurity organization called the Nuclear Threat Initiative (NTI).

In 2021, NTI is holding a workshop to support leaders from around the world in planning for the possibility of future pandemics.

Participants were asked to work on a scenario, “a serious global pandemic involving an uncommon strain of monkeypox virus spreading around the world.”

The NTI states that “the risk of diseasemonkey poxIt has been well documented for many years,” and the number of cases is increasing. Makes it clear viral to choose to attend this workshop.

The outbreak of infection is a fact of life. Therefore, the organizations that make their predictions and plans for them are not in themselves questionable.

diseasemonkey poxNot linked to the COVID-19 vaccine.

There are two forms of this claim: some point to the fact that the AstraZeneca vaccine uses a virus found in chimpanzees. which are adapted so that they cannot be reproduced and propagated.

These social media posts suggest a link between the chimpanzee-based vaccine and the smallpox outbreak.

However, monkey pox is caused by a virus that is completely different from the type found in the AstraZeneca vaccine, and is actually more common in rodents, not monkeys.

The second type of claim that is spread online is The coronavirus vaccine will suppress your immune system. This puts you at greater risk for other infections.

This claim has no basis in fact. Vaccine booster – does not deplete – your immune system This makes it more effective at targeting specific infections.

Although there are very few patients who develop autoimmune reactions to vaccines. where your body starts attacking itself (a rare cause of blood clots after astraZeneca). There is no evidence that vaccines suppress your immunity or alter your ability to fight off other diseases.

0 comment
0 FacebookTwitterEmail
Newer Posts
Older Posts